Safety and effectiveness of the sodium-glucose cotransporter inhibitor bexagliflozin in cats newly diagnosed with diabetes mellitus
Journal of Veterinary Internal Medicine · 2023-05-01 · 37 (3) · 915-924
DOI: 10.1111/jvim.16730 ↗At a glance
Journal article in Journal of Veterinary Internal Medicine, published online on 2023-05-01. Written by Michael J Hadd and 6 co-authors. Institution: IncreVet, Boston, Massachusetts, USA. Major MEDLINE topics: Cat Diseases, Diabetes Mellitus, Diabetic Ketoacidosis, Hyperglycemia. Cited 41 times so far (Crossref); 37 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: IncreVet, Inc..
Topics: Diabetes mellitus
Abstract (original language)
Background
Bexagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor. A pilot study has shown that bexagliflozin can decrease dependence on exogenous insulin in cats with diabetes mellitus (DM).
Objective
To evaluate the safety and effectiveness of bexagliflozin as a monotherapy for DM in previously untreated cats. Animals Eighty-four client-owned cats.
Methods
Historically controlled prospective open-label clinical trial. Cats were dosed PO with 15 mg bexagliflozin once daily for 56 days, with a 124-day extension to evaluate safety and treatment effect durability. The primary endpoint was the proportion of cats experiencing a decrease in hyperglycemia and improvement in clinical signs of hyperglycemia from baseline on day 56.
Results
Of 84 enrolled cats, 81 were evaluable on day 56, and 68 (84.0%) were treatment successes. Decreases in mean serum glucose, fructosamine, and β-hydroxybutyrate (β-OHB) concentrations were observed, and investigator assessments of cat neurological status, musculature, and hair coat quality improved. Owner evaluations of both cat and owner quality of life were favorable. The fructosamine half-life in diabetic cats was found to be 6.8 days. Commonly observed adverse events included emesis, diarrhea, anorexia, lethargy, and dehydration. Eight cats experienced serious adverse events, 3 of which led to death or euthanasia. The most important adverse event was euglycemic diabetic ketoacidosis, diagnosed in 3 cats and presumed present in a fourth. Conclusion and Clinical Importance Bexagliflozin decreased hyperglycemia and observed clinical signs in cats newly diagnosed with DM. As a once-daily PO medication, bexagliflozin may simplify management of DM in cats.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- IncreVet, Boston, Massachusetts, USA.
- Argenta, New Brunswick, New Jersey, USA.
- Bytown Cat Hospital, Ottawa, Ontario, Canada.
- Quakertown Veterinary Clinic, Quakertown, Pennsylvania, USA.
- Department of Veterinary Clinical Sciences, Purdue University College of Veterinary Medicine, West Lafayette, Indiana, USA.
ORCID profiles: Michael J Hadd, J Catharine Scott-Moncrieff
Funding
- IncreVet, Inc.
Cite
APA
Hadd, M. J., Bienhoff, S. E., Little, S. E., Geller, S., Ogne-Stevenson, J., Dupree, T. J., & Scott-Moncrieff, J. C. (2023). Safety and effectiveness of the sodium-glucose cotransporter inhibitor bexagliflozin in cats newly diagnosed with diabetes mellitus. Journal of Veterinary Internal Medicine, 37(3), 915-924. https://doi.org/10.1111/jvim.16730
Vancouver
Hadd MJ, Bienhoff SE, Little SE, Geller S, Ogne-Stevenson J, Dupree TJ, et al. Safety and effectiveness of the sodium-glucose cotransporter inhibitor bexagliflozin in cats newly diagnosed with diabetes mellitus. Journal of Veterinary Internal Medicine. 2023;37(3):915-924. doi:10.1111/jvim.16730
BibTeX
@article{Hadd2023,
author = {Hadd, Michael J and Bienhoff, Stephen E and Little, Susan E and Geller, Samuel and Ogne-Stevenson, Jennifer and Dupree, Thomas J and Scott-Moncrieff, J Catharine},
title = {Safety and effectiveness of the sodium-glucose cotransporter inhibitor bexagliflozin in cats newly diagnosed with diabetes mellitus},
journal = {Journal of Veterinary Internal Medicine},
year = {2023},
volume = {37},
number = {3},
pages = {915--924},
doi = {10.1111/jvim.16730}
}
EUVIMED